Keisuke Shirai MD

Oncology•Lebanon, NH

Head & Neck Cancer, Hospice & Palliative, Melanoma, Thoracic Cancer

Professor, Medicine, Dartmouth Cancer Center, Dartmouth Hitchcock Medical Center

Join to View Full Profile

1 Medical Center Dr# DhmcLebanon, NH 03756
Phone+1 603-650-7854

Education & Training

Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 2005 - 2008
UPMC Medical EducationResidency, Internal Medicine, 2002 - 2005
Faculty of Medicine Kyoto UniversityClass of 1997

Certifications & Licensure

VT State Medical License 2023 - 2026
NH State Medical License 2015 - 2025
SC State Medical License 2005 - 2017
PA State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer Start of enrollment: 2007 Jun 04
Completed
Phase 2
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Start of enrollment: 2009 Nov 01
Completed
Phase 1
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2009 Dec 16
Completed
Phase 1
A Study in Advanced Solid Tumors Start of enrollment: 2010 Jun 01
Completed
Phase 2
Everolimus Versus Placebo in Head and Neck Cancer Start of enrollment: 2010 Apr 01
Terminated
Phase 2
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
Terminated
Phase 1, Phase 2
Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells Start of enrollment: 2012 Oct 01
Terminated
Phase 1
Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer Start of enrollment: 2013 Mar 01
Completed
Phase 1
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Docetaxel and Lycopene in Metastatic Prostate Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 1
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma Start of enrollment: 2015 Oct 01
Active, not recruiting
Phase 1, Phase 2
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Start of enrollment: 2019 Nov 05
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.
Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka
The British Journal of Dermatology. 2025-01-24
Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on...
Ze Zhang, Kartik Sehgal, Keisuke Shirai, Rondi A Butler, John K Wiencke
NPJ Precision Oncology. 2024-11-18
2 citations
Depletion of conventional CD4T cells is required for robust priming and dissemination of tumor antigen-specific CD8T cells in the setting of anti-CD4 therapy.
Delaney E Ramirez, Christo P C Dragnev, Tyler G Searles, Nathaniel Spicer, Tiffany Chen
Journal for Immunotherapy of Cancer. 2024-11-09

Press Mentions

Resident and Circulating Memory T Cells Persist for Years in Melanoma Patients with Durable Responses to ImmunotherapyMarch 24th, 2021
At the Hospitals: Aug. 18, 2019August 17th, 2019
Dartmouth-Hitchcock Health Funds $1M Annually for Dedicated Cancer Clinician Research TimeJuly 31st, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member